Effectiveness and Safety of Adalimumab, Etanercept and Ustekinumab for Severe Psoriasis in Children Under 12 Years of Age: A French-Italian Daily Practice Cohort (BiPe Jr) - Sorbonne Université Access content directly
Journal Articles Pediatric Drugs Year : 2022

Effectiveness and Safety of Adalimumab, Etanercept and Ustekinumab for Severe Psoriasis in Children Under 12 Years of Age: A French-Italian Daily Practice Cohort (BiPe Jr)

Vito Di Lernia
Emmanuel Mahé

Domains

Dermatology
Fichier principal
Vignette du fichier
BiPe Jr Article Ped Drugs.pdf (470.9 Ko) Télécharger le fichier
Origin Files produced by the author(s)

Dates and versions

hal-03906645 , version 1 (19-12-2022)

Identifiers

Cite

Jinane Zitouni, Alain Beauchet, Raphaëlle Curmin, Vito Di Lernia, Anne-Claire Bursztejn, et al.. Effectiveness and Safety of Adalimumab, Etanercept and Ustekinumab for Severe Psoriasis in Children Under 12 Years of Age: A French-Italian Daily Practice Cohort (BiPe Jr). Pediatric Drugs, 2022, 24 (3), pp.281-292. ⟨10.1007/s40272-022-00501-6⟩. ⟨hal-03906645⟩
77 View
179 Download

Altmetric

Share

Gmail Mastodon Facebook X LinkedIn More